<DOC>
	<DOCNO>NCT01444131</DOCNO>
	<brief_summary>The purpose study test whether addition nicotine patch varenicline increase smoke cessation success rate whether combination safe .</brief_summary>
	<brief_title>Varenicline Combination With Nicotine Replacement Therapy Smoking Cessation</brief_title>
	<detailed_description>This phase-II multicenter study involve 438 smoker , conduct 7 site South Africa , 6 month . In randomized 1:1 allocation varenicline tartrate 1 mg twice daily , give incremental dosage first week target quit date ( TQD ) , compare varenicline tartrate dose combine 15mg nicotine patch . The nicotine patch ( active placebo ) provide McNeil . The patch give 2 week prior TQD . Treatment duration TQD 12 week varenicline taper week 13 . A total 12 clinic visit 1 telephonic contact plan 6-month study duration . The main efficacy outcome 4-week continuous abstinence rate last four week treatment , i.e . week 9 - 12 . Efficacy assessment base Nicotine Use Inventory measurement end-expiratory exhaled carbon monoxide . Safety assessment base adverse event evaluation , special attention give occurrence nausea pretreatment period , well neuro-psychiatric symptom depression suicidal ideation . Participants subject invasive procedure . This protocol base current evidence two abstract present European Respiratory Society Conference Vienna , September 2009 , combination varenicline tartrate nicotine replacement therapy indicate superior efficacy cessation rate , also excellent good safety profile . This study relate area pharmacotherapy smoking cessation , answer frequently ask question . Importantly , several lead pulmonologists experience smoking cessation South Africa express keen interest participate study .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>1 . Current cigarette smoker , male female , age 1875 year ( limit inclusive ) , motivate stop smoking . 2 . Have smoke average least 10 cigarette per day past year month prior screen , period abstinence great 3 month past year . 3 . Women childbearing potential ( WCBP ) may include provide pregnant , nursing , meet follow criterion : instruct agree avoid pregnancy 30 day last dose study medication negative screen test ( betaHCG ) screen agree use least one birth control method ( oral contraceptive , IUD , implantable injectable contraceptive least 1 month prior enter study continue use least 30 day last dose study medication , use barrier method contraception ( p.e.condom , diaphragm spermicide ) participate study least 30 day last dose study medication ; abstinence . 4 . Patients must serious unstable disease past 6 month . 5 . Patients must able outpatient , assess clinical setting , able willing comply study visit treatment nontreatment period . 6 . Only one subject per household may participate . 1 . Patients currently suffer depression diagnose depression treat antidepressant within past 12 month . 2 . Patients past present history psychosis , panic disorder , bipolar disorder . 3 . Patients severe chronic obstructive pulmonary disease ( COPD ) . 4 . Patients clinically significant cardiovascular disease past 6 month . myocardial infarction , coronary artery bypass graft ( CABG ) , percutaneous transluminal coronary angioplasty ( PTCA ) , severe unstable angina , serious arrhythmia , clinically significant ECG conduction abnormality . 5 . Patients uncontrolled hypertension systolic blood pressure great 150mmHg diastolic pressure great 95mmHg screen baseline . 6 . Patients clinically significant neurological disorder cerebrovascular disease ( example , stroke , transient ischemic attack , etc . ) past 6 month . 7 . Patients history clinically significant endocrine disorder gastrointestinal disease , include insulin dependent diabetes mellitus , uncontrolled hyperthyroidism , active peptic ulcer . 8 . Patients clinically significant hepatic renal impairment clinically significant abnormal laboratory test value . 9 . Patients history cancer ( cure basal cell squamous cell carcinoma skin allow ) . 10 . Patients history clinically significant allergic reaction drug ( example , severe cutaneous and/or systemic allergic reaction ) . 11 . Patients history drug ( except nicotine ) alcohol abuse dependence within past 12 month . 12 . Patients body mass index ( BMI ) less 15 great 38 wear indoor clothing without shoe . No subject enrol weight le 45.5kg ( 100 pound ) . 13 . Patients previously enrol study include varenicline . 14 . Patients used nicotine replacement therapy within last 6 month . 15 . Patients take another investigational drug within 30 day 5 halflives ( whichever longer ) Baseline visit within 30 day study completion . 16 . Use prohibit medication : antidepressant , include bupropion ; antipsychotic agent ; mood stabilizer ; naltrexone ; steroid ( inhaled topical steroid permit ) ; insulin . 17 . Patients agree completely abstain use noncigarette tobacco product ( include example , pipe tobacco , cigar , snuff , chew tobacco , etc . ) marijuana study participation . 18 . Patients intend donate blood blood component receive study drug within 1 month completion study treatment . 19 . Patients unable/or unlikely comprehend follow study protocol , include patient unable and/or unwilling participate nontreatment followup . Patients , investigator 's opinion , unlikely commit 6 monthlong study . 20 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Smoking</keyword>
	<keyword>Smoking cessation</keyword>
	<keyword>Pharmaceutical aid</keyword>
</DOC>